Search results
Results from the WOW.Com Content Network
This is a shortened version of the fifteenth chapter of the ICD-9: Certain Conditions originating in the Perinatal Period. It covers ICD codes 760 to 779. The full chapter can be found on pages 439 to 453 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1.
This is a shortened version of the eleventh chapter of the ICD-9: Complications of Pregnancy, Childbirth, and the Puerperium. It covers ICD codes 630 to 679. The full chapter can be found on pages 355 to 378 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1.
The drug crosses the placenta and affects the fetus during the gestational stage of pregnancy. [89] Methamphetamine use in pregnancy may lead to babies born with an earlier gestational age at delivery (pre-term), lower birth weight, and smaller head circumference. [ 89 ]
Proprietary database identifiers include those assigned by First Databank, Micromedex, MediSpan, Gold Standard Drug Database (published by Elsevier), and Cerner Multum MediSource Lexicon; these are cross-indexed by RxNorm, which also assigns a unique identifier (RxCUI) to every combination of active ingredient and dose level.
Fetal warfarin syndrome is a disorder of the embryo which occurs in a child whose mother took the medication warfarin (brand name: Coumadin) during pregnancy.Resulting abnormalities include low birth weight, slower growth, intellectual disability, deafness, small head size, and malformed bones, cartilage, and joints.
There is a risk that the drug is toxic to fetuses throughout the second and third trimesters. Group 9 There is a risk that the drug causes prenatal complications or abnormalities. Group 10 There is a risk that the drug causes hormone specific action on the human fetus. Group 11 There is a known risk that the drug is a mutagen/carcinogen.
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: The drug or other substance has a high potential for abuse.
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs , ranked by sales.